Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Public ClinicalTrials.gov record NCT05891171. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
Study identification
- NCT ID
- NCT05891171
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 40 participants
Conditions and interventions
Conditions
- Advanced Cancer
- Advanced Malignancies
- Bladder Cancer
- Cervical Cancer
- Esophageal Cancer
- Gastric Cancer
- Gastroesophageal-junction Cancer (GEJ)
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Non-Small Cell Lung Cancer (NSCLC)
- Ovarian Cancer
- Renal Cell Carcinoma (RCC)
- Triple Negative Breast Cancer (TNBC)
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 13, 2023 (Actual)
- Primary completion
- Sep 2027 (Estimated)
- Completion
- Sep 2027 (Estimated)
- Last update posted
- Sep 29, 2026
2023 – 2027
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Phoenix | Arizona | 85054 | — |
| Research Site | Jacksonville | Florida | 32224 | — |
| Research Site | Lake City | Florida | 32024 | — |
| Research Site | Hinsdale | Illinois | 60521 | — |
| Research Site | Detroit | Michigan | 48201 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Research Site | New Brunswick | New Jersey | 08901 | — |
| Research Site | Canton | Ohio | 44718 | — |
| Research Site | Cleveland | Ohio | 44106 | — |
| Research Site | Irving | Texas | 75039 | — |
| Research Site | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05891171, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 29, 2026 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05891171 live on ClinicalTrials.gov.